lymphotoxin β receptor | Tumour necrosis factor (TNF) receptor family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

lymphotoxin β receptor

  Target has curated data in GtoImmuPdb

Target id: 1872

Nomenclature: lymphotoxin β receptor

Systematic Nomenclature: TNFRSF3

Family: Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 435 12p13 LTBR lymphotoxin beta receptor
Mouse 1 415 Ltbr lymphotoxin B receptor
Rat - - Ltbr lymphotoxin beta receptor
Previous and Unofficial Names
CD18 | LTbetaR | LT-beta receptor | LTBR | lymphotoxin beta receptor (TNFR superfamily, member 3) | TNFCR | TNFR2-RP | TNF receptor-related protein | TNFR III
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Adaptor proteins (Human)
TRAF3, TRAF4, TRAF5
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Parameter Reference
LIGHT {Sp: Human} Hs - - -
lymphotoxin β2α1 heterotrimer {Sp: Human} N/A - - -
Immunopharmacology Comments
Interaction of the lymphotoxin β receptor (LTBR) with its ligand is required for the development and organization of the secondary lymphoid organs and is involved in chemokine release (reported to induce interleukin 8 gene expression [2]). The LTBR pathway also drives expression of homeostatic chemokines (CCL19, CCL21, CXCL13) that are associated with the pathological development of ectopic lymphoid-like follicles in the exocrine glands of patients with Sjögren's syndrome. Consequently the CXCL13/LTBR axis is considered as a potential therapeutic target in conditions like Sjögren's syndrome. This is evidenced by the development of pharmaceutical agents that block LTBR activity being advanced to clinical trials (e.g. baminercept (BG9924; Biogen) which is a soluble LTBR-IgG Fc fusion protein [1]). BG9924, was primarily evaluated in clinical trials for active rheumatoid arthritis (RA; NCT00458861). However development in RA was terminated because interim analysis of trial data indicated that BG9924 therapy failed to meet the primary endpoint.
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 2 GO processes
GO:0006954 inflammatory response IBA
click arrow to show/hide IEA associations
GO:0043011 myeloid dendritic cell differentiation IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 2 GO processes
GO:0005031 tumor necrosis factor-activated receptor activity IBA
GO:0033209 tumor necrosis factor-mediated signaling pathway TAS
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0043011 myeloid dendritic cell differentiation IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0043011 myeloid dendritic cell differentiation IEA

References

Show »

1. Bienkowska J, Allaire N, Thai A, Goyal J, Plavina T, Nirula A, Weaver M, Newman C, Petri M, Beckman E et al.. (2014) Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS ONE, 9 (11): e112545. [PMID:25405351]

2. Chang YH, Hsieh SL, Chen MC, Lin WW. (2002) Lymphotoxin beta receptor induces interleukin 8 gene expression via NF-kappaB and AP-1 activation. Exp. Cell Res., 278 (2): 166-74. [PMID:12169272]

Contributors

Show »

How to cite this page

David MacEwan.
Tumour necrosis factor (TNF) receptor family: lymphotoxin β receptor. Last modified on 26/03/2018. Accessed on 19/03/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1872.